Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing

NCT ID: NCT07254442

Last Updated: 2025-11-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-12-01

Study Completion Date

2022-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims to investigate the impact of medications containing the active ingredients hydroxychloroquine and favipiravir on the auditory system, as well as to examine the effect of COVID-19 on hearing and its potential relationship with medication use and COVID-19 vaccine dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hearing COVID - 19 Ototoxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Group that has not had Covid-19

Hearing tests

Intervention Type DIAGNOSTIC_TEST

Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.

Medication Group

The group that had Covid-19 and used medication

Hearing tests

Intervention Type DIAGNOSTIC_TEST

Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.

Non-medication group

The group that had Covid-19 and did not use medication

Hearing tests

Intervention Type DIAGNOSTIC_TEST

Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hearing tests

Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age between 18 and 35 For the Medication group: Having had COVID-19 and using COVID-19 medications For the Non-Medication group: Having had COVID-19 and not using COVID-19 medications For the Control group: Having never had COVID-19

Exclusion Criteria

Previously diagnosed with hearing loss Use of ototoxic medications other than those specified Pathology detected during tympanometric evaluation or otoscopic examination Chronic disease Family history of hearing loss History of meningitis Neurological disorders Acute or chronic ear infection Admission to intensive care
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zonguldak Bulent Ecevit University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Azize Arzu KÖROĞLU KOÇYİĞİT

Audiologist, Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Biruni University

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1919B012102481

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2021/61-18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prevention of Noise-induced Hearing Loss
NCT02049073 WITHDRAWN PHASE1/PHASE2
Vaccination for Middle Ear Infection
NCT00001605 COMPLETED PHASE1